Tresiba

Tresiba is a long-acting basal insulin analog used in the management of diabetes mellitus. It contains the active ingredient insulin degludec, which is designed to provide a steady and prolonged blood glucose-lowering effect. Developed by the Danish pharmaceutical company Novo Nordisk, it received its first global approval from the European Medicines Agency in 2012. Its unique pharmacological profile offers a consistent action profile with a duration of action exceeding 42 hours.

Medical uses

Tresiba is indicated for the treatment of type 1 diabetes and type 2 diabetes in adults, and for type 1 diabetes in children and adolescents aged one year and above. It serves as a basal insulin to control blood glucose levels throughout the day and night. Clinical trials, such as those presented at the American Diabetes Association Scientific Sessions, have demonstrated its efficacy in achieving glycemic control as measured by HbA1c levels. It can be administered once daily at any time, offering flexibility, though the Food and Drug Administration recommends consistency in timing.

Adverse effects

The most common adverse effect is hypoglycemia, which can be severe. Other potential reactions include injection site reactions such as lipodystrophy, pruritus, and rash. Allergic reactions, though rare, can occur and may present as anaphylaxis. Weight gain has also been observed in some patients. The Institute for Safe Medication Practices monitors reports of such events, and warnings are included in the prescribing information mandated by regulatory bodies like the European Medicines Agency.

Pharmacology

Insulin degludec in Tresiba forms multi-hexamers upon subcutaneous injection, creating a depot from which monomers are slowly and continuously released into the bloodstream. This mechanism results in a flat and stable pharmacokinetic profile. Its terminal half-life is approximately 25 hours, contributing to an ultra-long duration of action. The molecule is designed with a fatty acid side chain that promotes reversible binding to albumin in the interstitial fluid and plasma, further prolonging its effect. Its pharmacodynamic action mimics the physiological basal secretion of the pancreas.

History

The development of insulin degludec was led by researchers at Novo Nordisk in Bagsværd, Denmark. The pivotal phase 3 clinical trial program, called BEGIN, involved thousands of patients across multiple countries. The European Medicines Agency granted marketing authorization in 2012, followed by approval from the Food and Drug Administration in the United States in 2015. The FDA's review process included an assessment of cardiovascular outcomes data. Its approval represented a significant advancement in the lineage of long-acting insulin analogs, which includes insulin glargine and insulin detemir.

Society and culture

Tresiba is a significant product for Novo Nordisk, contributing substantially to its revenue within the competitive global diabetes care market. It has been the subject of direct-to-consumer advertising campaigns, particularly in the United States. The cost of therapy has been a point of discussion in healthcare systems, with entities like the National Health Service in the United Kingdom conducting health technology assessments. The drug has also been featured in educational programs by the American Association of Clinical Endocrinology and is included in treatment guidelines from the American Diabetes Association.

Category:Antidiabetic drugs Category:Insulins Category:Novo Nordisk